Johansson P, Andréasson B
Section of Haematology and Coagulation, Sahlgrenska University Hospital, Göteborg and Uddevalla Hospital, Uddevalla, Sweden.
Clin Lab Haematol. 2006 Aug;28(4):233-6. doi: 10.1111/j.1365-2257.2006.00789.x.
The determination of serum/plasma erythropoietin (EPO) concentration has gained widespread use in the diagnosis of polycythaemia vera (PV). A reduced EPO concentration in a newly diagnosed essential thrombocythaemia (ET) seems to be a risk factor for thromboembolic events. In this study plasma EPO concentration was determined before and after initiated hydroxyurea (HU) therapy, 14 patients with PV or ET were included. After 1 month on HU therapy 11 of 14 patients had increased their EPO concentration compared with prior to medication. The plasma EPO was increased in all, except one patient, after 4 months HU therapy. If EPO is incorporated in the diagnostic or prognostic procedures it should be determined before myelosuppressive therapy is initiated.
血清/血浆促红细胞生成素（EPO）浓度的测定在真性红细胞增多症（PV）的诊断中已得到广泛应用。新诊断的原发性血小板增多症（ET）患者EPO浓度降低似乎是血栓栓塞事件的一个危险因素。在本研究中，测定了14例PV或ET患者在开始羟基脲（HU）治疗前后的血浆EPO浓度。接受HU治疗1个月后，14例患者中有11例的EPO浓度较用药前有所升高。HU治疗4个月后，除1例患者外，所有患者的血浆EPO均升高。如果将EPO纳入诊断或预后评估程序，则应在开始骨髓抑制治疗之前进行测定。
